Chugai Pharmaceutical, part of the Roche group headquartered in Tokyo, has ventured into the aging disease drug development arena through a strategic collaboration with Pfizer-allied Gero. This partnership highlights growing interest among pharmaceutical giants to target age-related conditions, signaling an expansion of research and development efforts into longevity therapeutics.